This trial investigates whether supervised training in combination with hormonal substitution therapy has an impact on body composition, cardiovascular risk, risk for dementia, osteoporosis and insulin sensitivity in postmenopausal women.
Postmenopausal women (diagnosed by physician) with complaints due to menopause
Indication for hormonal substitution therapy (except for the control group)
Good general health
BMI: 20-30 kg/m2
None
Parallel
Exercise program
Other interventionThe intervention consists of a supervised exercise program
Hormonal substitution therapy per SOC
DrugSubjects take hormonal substitution therapy per standard of care
6
Treatment groupsSee each treatment group below.
Evaluation of the cardiovascular risk
The cardiovascular risk will be estimated by blood- and urine analysis, blood pressure and a AGE (i.e. Advanced Glycation End products)-reader. There are three timepoints of measurement; once at inclusion, once at 12 weeks, and once at 24 weeks.
Evaluation of the insulin sensitivity
The insulin sensitivity will be estimated by blood- and urine analysis and a AGE (i.e. Advanced Glycation End products)-reader. There are three timepoints of measurement; once at inclusion, once at 12 weeks, and once at 24 weeks.
Evaluation of the body composition
The body composition will be measured using bioimpedance technology (Tanita-scale). The body composition will be measured three times; once at inclusion, once at 12 weeks and once at 24 weeks.
Evaluation of the muscle mass
The musle mass will be evaluated by performing a maximal effort test (i.e. cycling test). This test will be performed three times; once at inclusion, once at 12 weeks, and once at 24 weeks.
Click on the lead sponsor to view all of their trials.
